[vc_row full_width=”stretch_row_content_no_spaces” css=”.vc_custom_1627982865062{background-image: url(https://pepgra.com/wp-content/uploads/2021/08/Device-Manufacturers-Banner.jpg?id=4211) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}” el_class=”aca-bac”][vc_column][vc_column_text]
Patient Centricity in Clinical Trials
[/vc_column_text][/vc_column][/vc_row][vc_row css=”.vc_custom_1627982791234{padding-top: 3% !important;}” el_class=”under-tit”][vc_column width=”1/3″][vc_empty_space height=”60px”][vc_tta_accordion active_section=”1″ title=”Clinical Research Monitoring”][vc_tta_section title=”Pharmaceutical Industry” el_class=”cliniresearch”][vc_column_text]
- The Real-Time Oncology Review (RTOR) Pilot Program for New Molecular Entities Approvals
- FDA Guidance for Human Gene Therapy for Hemophilia A & B
- Patient Centricity in Clinical Trials
- How to improve your chances of getting FDA approval
- Biomarker Applications in Drug Discovery and Development
- Risk-based monitoring in clinical research
[/vc_column_text][/vc_tta_section][/vc_tta_accordion][/vc_column][vc_column width=”2/3″][vc_row_inner][vc_column_inner width=”1/2″][/vc_column_inner][vc_column_inner width=”1/2″][vc_column_text]
[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_column_text]
Patient Centricity in Clinical Trials
[/vc_column_text][vc_column_text]The clinical research industry is undergoing a tremendous transformation right now. Companies are constantly seeking new and inventive ways to speed up new drugs on the market. Companies are becoming more transparent, and patients are no longer seen as “subjects” who create data but as informed collaborators whose involvement is “critical” to the overall success of trials, resulting in the concept of “patient-centric trials.”
- Although the science underpinning medication development and clinical trials has become increasingly complicated, the digital age has accelerated patient centricity. Many of the obstacles that formerly separated pharmaceutical firms, physicians, and patients have been lowered or eliminated due to easy access to trustworthy medical information. Physicians and pharmaceutical firms no longer have exclusive access to knowledge about illnesses, diseases, and medical conditions, allowing even people with the highest regard for their doctors to augment physician-provided material with their own layman’s research.
- As a result, patient expectations have shifted. Patients expect to be active applicants in their health care, and clinical trial participation will be less transactional and more partnership-oriented with the advent of enhanced point-of-location services (i.e., Amazon delivery vs travelling to shopping malls) and consumer-direct measurement of health (i.e., Fit Bit and Apple Watch health metrics). In essence, patient-centricity is about easing the load on patients.
- Innovation is essential when there is a collection of solutions that have shown to be effective and efficient assistance for patients and can be adopted quickly. Still, it shouldn’t be the only path we pursue as an industry. Similarly, while the cost of a patient-centric clinical trial should be considered, this should not prevent sponsors and CROs from using cost-effective and successful techniques.
[/vc_column_text][vc_column_text]
References
Sharma NS. Patient-centric approach for clinical trials: Current trend and new opportunities. Perspect Clin Res. 2015;6(3):134-138. doi:10.4103/2229-3485.159936
[/vc_column_text][/vc_column][/vc_row]
